{
  "source": "PA-Notification-Cosentyx.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1152-13\nProgram Prior Authorization/Notification\nMedication Cosentyx® (secukinumab) prefilled syringe or Sensoready pen\nP&T Approval Date 2/2015, 3/2016, 3/2017, 3/2018, 2/2019, 2/2020, 7/2020, 7/2021, 2/2022,\n2/2023, 7/2023, 1/2024, 1/2025\nEffective Date 4/1/2025\n1. Background:\nCosentyx (secukinumab) is a human interleukin-17A antagonist indicated for the treatment of\nmoderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic\ntherapy or phototherapy, active psoriatic arthritis (PsA) in patients 2 years of age and older, adults\nwith active ankylosing spondylitis (AS) or non-radiographic axial spondyloarthritis (nr-axSpA)\nwith objective signs of inflammation, active enthesitis-related arthritis (ERA) in patients 4 years of\nage and older, and adults with moderate to severe hidradenitis (HS).\n2. Coverage Criteriaa:\nA. Plaque Psoriasis\n1. Initial Authorization\na. Cosentyx will be approved based on both of the following criteria:\n(1) Diagnosis of moderate to severe plaque psoriasis\n-AND-\n(2) Patient is not receiving Cosentyx in combination with another targeted\nimmunomodulator [e.g., adalimumab, Bimzelx (bimekizumab-bkzx), Cimzia\n(certolizumab), Enbrel (etanercept), Ilumya (tildrakizumab), Olumiant\n(baricitinib), Otezla (apremilast), Simponi (golimumab), Orencia (abatacept),\nRinvoq (upadacitinib), Siliq (brodalumab), Skyrizi (risankizumab), Sotyktu\n(deucravacitinib), Stelara (ustekinumab), Taltz (ixekizumab), Tremfya\n(guselkumab), Xeljanz (tofacitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Cosentyx will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Cosentyx therapy\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n1\n(2) Patient is not receiving Cosentyx in combination with another targeted\nimmunomodulator [e.g., adalimumab, Bimzelx (bimekizumab-bkzx), Cimzia\n(certolizumab), Enbr",
    " UnitedHealthcare Services, Inc.\n1\n(2) Patient is not receiving Cosentyx in combination with another targeted\nimmunomodulator [e.g., adalimumab, Bimzelx (bimekizumab-bkzx), Cimzia\n(certolizumab), Enbrel (etanercept), Ilumya (tildrakizumab), Olumiant\n(baricitinib), Otezla (apremilast), Simponi (golimumab), Orencia (abatacept),\nRinvoq (upadacitinib), Siliq (brodalumab), Skyrizi (risankizumab), Sotyktu\n(deucravacitinib), Stelara (ustekinumab), Taltz (ixekizumab), Tremfya\n(guselkumab), Xeljanz (tofacitinib)]\nAuthorization will be issued for 12 months.\nB. Psoriatic Arthritis\n1. Initial Authorization\na. Cosentyx will be approved based on both of the following criteria:\n(1) Diagnosis of active psoriatic arthritis\n-AND-\n(2) Patient is not receiving Cosentyx in combination with another targeted\nimmunomodulator [e.g., adalimumab, Bimzelx (bimekizumab-bkzx), Cimzia\n(certolizumab), Enbrel (etanercept), Olumiant (baricitinib), Orencia (abatacept),\nOtezla (apremilast), Rinvoq (upadacitinib), Simponi (golimumab), Skyrizi\n(risankizumab), Stelara (ustekinumab), Taltz (ixekizumab), Tremfya\n(guselkumab), Xeljanz/Xeljanz XR (tofacitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Cosentyx will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Cosentyx therapy\n-AND-\n(2) Patient is not receiving Cosentyx in combination with another targeted\nimmunomodulator [e.g., adalimumab, Bimzelx (bimekizumab-bkzx), Cimzia\n(certolizumab), Enbrel (etanercept), Olumiant (baricitinib), Orencia (abatacept),\nOtezla (apremilast), Rinvoq (upadacitinib), Simponi (golimumab), Skyrizi\n(risankizumab), Stelara (ustekinumab), Taltz (ixekizumab), Tremfya\n(guselkumab), Xeljanz/Xeljanz XR (tofacitinib)]\nAuthorization will be issued for 12 months.\nC. Ankylosing Spondylitis or Non-radiographic Axial Spondyloarthritis\n1. Initial Authorization\n© 2025 UnitedHealthcare Services, Inc.\n2\na. Cosentyx will be approved based on both of the following c",
    "s.\nC. Ankylosing Spondylitis or Non-radiographic Axial Spondyloarthritis\n1. Initial Authorization\n© 2025 UnitedHealthcare Services, Inc.\n2\na. Cosentyx will be approved based on both of the following criteria:\n(1) Diagnosis of active ankylosing spondylitis or active non-radiographic axial\nspondyloarthritis\n-AND-\n(2) Patient is not receiving Cosentyx in combination with another targeted\nimmunomodulator [e.g., adalimumab, Bimzelx (bimekizumab-bkzx), Cimzia\n(certolizumab), Enbrel (etanercept), Olumiant (baricitinib), Orencia (abatacept),\nSimponi (golimumab), Rinvoq (upadacitinib), Taltz (ixekizumab), Xeljanz\n(tofacitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Cosentyx will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Cosentyx therapy\n-AND-\n(2) Patient is not receiving Cosentyx in combination with another targeted\nimmunomodulator [e.g., adalimumab, Bimzelx (bimekizumab-bkzx), Cimzia\n(certolizumab), Enbrel (etanercept), Olumiant (baricitinib), Orencia (abatacept),\nSimponi (golimumab), Rinvoq (upadacitinib), Taltz (ixekizumab), Xeljanz\n(tofacitinib)]\nAuthorization will be issued for 12 months.\nD. Enthesitis-Related Arthritis\n1. Initial Authorization\na. Cosentyx will be approved based on both of the following criteria:\n(1) Diagnosis of active enthesitis-related arthritis\n-AND-\n(2) Patient is not receiving Cosentyx in combination with another targeted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel\n(etanercept), Rinvoq (upadacitinib), Simponi (golimumab), Xeljanz (tofacitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Cosentyx will be approved based on both of the following criteria:\n© 2025 UnitedHealthcare Services, Inc.\n3\n(1) Documentation of positive clinical response to Cosentyx therapy\n-AND-\n(2) Patient is not receiving Cosentyx in combination with another targeted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel\n(etanercept),",
    "ve clinical response to Cosentyx therapy\n-AND-\n(2) Patient is not receiving Cosentyx in combination with another targeted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel\n(etanercept), Rinvoq (upadacitinib), Simponi (golimumab), Xeljanz (tofacitinib)]\nAuthorization will be issued for 12 months.\nE. Hidradenitis Suppurativa (HS)\n1. Initial Authorization\na. Cosentyx will be approved based on both of the following criteria:\n(1) Diagnosis of moderate to severe hidradenitis suppurativa\n-AND-\n(2) Patient is not receiving Cosentyx in combination with another targeted\nimmunomodulator [e.g., adalimumab, Bimzelx (bimekizumab-bkzx)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Cosentyx will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Cosentyx therapy.\n-AND-\n(2) Patient is not receiving Cosentyx in combination with another targeted\nimmunomodulator [e.g., adalimumab, Bimzelx (bimekizumab-bkzx)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits and/or Step Therapy may be in place.\n© 2025 UnitedHealthcare Services, Inc.\n4\n4. Reference:\n1. Cosentyx [package insert]. East Hanover, NJ. Novartis Pharmaceuticals Corp.; October 2024.\nProgram Prior Authorization/Notification - Cosentyx (secukinumab)\nChange Control\n2/2015 New program.\n3/2016 Annual review. Updated background information and clinical criteria to\ninclude the two new indications for active psoriatic arthrit",
    "n - Cosentyx (secukinumab)\nChange Control\n2/2015 New program.\n3/2016 Annual review. Updated background information and clinical criteria to\ninclude the two new indications for active psoriatic arthritis and active\nankylosing spondylitis. Added Otezla to the criteria for medications that\ncannot be used in combination with Cosentyx for plaque psoriasis and\npsoriatic arthritis. Updated reference.\n3/2017 Annual review with no changes to criteria.\n3/2018 Annual review with no changes to criteria. Updated reference.\n2/2019 Annual review with no changes to criteria. Updated reference.\n2/2020 Annual review with no changes to criteria. Updated reference.\n7/2020 Updated background and criteria to include new indication for active\nnon-radiographic axial spondyloarthritis. Changed reauthorization\nduration to 12 months. Updated reference.\n7/2021 Annual review. Updated background to include expanded indication\nfor moderate to severe plaque psoriasis to pediatric patients 6 years and\nolder. Updated reference.\n2/2022 Updated background and clinical criteria with new indication for ERA.\nUpdated reference.\n2/2023 Annual review. Updated listed examples from Humira to adalimumab\nand added Rinvoq. Added state mandate footnote.\n7/2023 Updated not receiving in combination language to targeted\nimmunomodulator and updated examples.\n1/2024 Added coverage criteria for new indication for Hidradenitis Suppurativa\n(HS). Updated background and reference.\n1/2025 Annual review with no changes to clinical criteria. Updated examples\nwith no change to clinical intent. Updated reference.\n© 2025 UnitedHealthcare Services, Inc.\n5"
  ]
}